Interferon versus Methotrexate in Intermediate Uveitis With Macular Edema: Results of a Randomized Controlled Clinical Trial

Mackensen, Friederike; Jakob, Eva; Springer, C.; Dobner, Bianca C.; Wiehler, U.; Weimer, P.; Rohrschneider, Klaus; Fiehn, Christoph; Max, Regina; Storch-Hagenlocher, B.; Becker, Matthias

doi:10.1016/j.ajo.2013.05.002

Cited by 93 publications

(52 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Details of the excluded full-text articles with reasons for exclusion are presented in Appendix 2. Seventeen potentially relevant articles (relating to 16 studies) were retained for potential inclusion in meta-analyses; 13 studies 32,33,[57][58][59][60][61][62][63][64][65][66][67] were related to comparators within the scope of the review and three studies (four articles [46][47][48]68 ) evaluated ADA or DEX 700. It was not possible to include any of the 13 studies of comparators within a NMA (the reasons why this was not possible, and a summary of the 13 studies, are provided in Indirect comparison of treatments: rationale for not undertaking and Table 24).…”

Section: Results Of the Clinical Effectiveness Reviewmentioning

confidence: 99%

“…In addition to the trials of DEX 700 (HURON 48 ) and ADA (VISUAL I 46 and II 47 ), 13 additional trials of relevant comparators were identified. 32,33,[57][58][59][60][61][62][63][64][65][66][67] Unfortunately, it was considered infeasible and inappropriate to conduct a NMA for the reasons outlined in Table 24. However, a brief summary of all identified trials of relevant comparators is provided in this section for information: study characteristics are provided in Table 25 and a summary of reported outcomes is provided in …”

Section: Consideration Of Indirect Comparisons For All Studies Of CLImentioning

confidence: 99%

See 1 more Smart Citation

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

Squires

Poku

Bermejo

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

Declared competing interests of authors: Fahd Quhill has received personal fees from Allergan for participation in medical education and training, and has participated in advisory boards given his clinical expertise in the role of steroids in diabetic macular oedema. He has also received support from Allergan to attend international conferences.Published November 2017 DOI: 10.3310/hta21680 This report should be referenced as follows: This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: journals.library@nihr.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 15/64/07. The protocol was agreed in June 2016. The assessment report began editorial review in December 2016 and was accepted for publication in May 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expre...

show abstract

Section: Results Of the Clinical Effectiveness Reviewmentioning

confidence: 99%

Section: Consideration Of Indirect Comparisons For All Studies Of CLImentioning

confidence: 99%

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

Squires

Poku

Bermejo

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 Retinal function can improve in response to treatment and in a randomized trial of treatment with methotrexate versus interferon-b for patients with intermediate uveitis and macular edema, both visual acuity and retinal contrast sensitivity improved in both arms. However in those given interferon-b both visual acuity and central retinal contrast sensitivity improved to a greater degree, indicating ongoing recovery after resolution of macular edema or possibly that interferon-b has a neuroprotective effect (Mackensen et al, 2013). This has been corroborated by a study of multiple sclerosis patients where treatment with interferon-b resulted in reduction in brain atrophy, suggesting a degree of neuroregeneration (Zivadinov et al, 2008).…”

Section: Microperimetry In Uveitic Macular Edemamentioning

confidence: 89%

Functional outcome of macular edema in different retinal disorders

Tomkins-Netzer¹,

Ismetova

Bar

et al. 2015

Progress in Retinal and Eye Research

View full text Add to dashboard Cite

“…IFN-a has demonstrated efficacy in treatment of Behçet's-related uveitis [107][108][109], and small series have suggested that IFN-a is beneficial in refractory uveitic macular edema [110][111][112]. IFN-b is commonly used to treat multiple sclerosis and may prove beneficial in intermediate uveitis with macular edema [113].…”

Section: Expert Commentary and Five-year Viewmentioning

confidence: 98%